TMU, 3D Biotech, and Sentronic, Cross-domain cooperation between industry, academia,and medicine accelerates new development of high-end medical materials

2022/12/08

---

3D Biotech, a spin-off company from Taipei Medical University, has joined hands with electronic distributor Sentronic to work together towards high-end medical device development. Sentronic has been deeply involved in Japan for decades, integrating international resource advantages, and inheriting Japanese advanced technology. For the first time, Sentronic cross-domain cooperated with 3D Biotech. Together, they developed BioSpace Surface Functionalization (BSSF) for metal surface treatment, which is further applied to high-end medical devices such as dental implants and cardiovascular stent systems. Taipei Medical University and the six affiliated hospitals participate as the providers of clinical trials and research resources. The three parties have joined forces and were launched in 2022 on December 8. The memorandum of cooperation was signed at Taipei Medical University to begin new development of high-end medical devices.

(3D Biotech Chairman Keng-Liang Ou (left), Taipei Medical University President Chien-Huang Lin (center), and Sentronic Chairman Tonko Tsai (right) signed a memorandum of cooperation.)

(From left to right: President Tso-Hsiao Chen of Wanfang Hospital, Vice President Mai-Szu Wu of Taipei Medical University, Vice President Chieh-Hsi Wu of Taipei Medical University, Director Tsu-Der Lee of Taipei Medical University, Chairman Keng-Liang Ou of 3D Biotech, President Chien-Huang Lin of Taipei Medical University, former Minister of Health and Welfare Shih-Chung Chen, Chairman of Sentronic Tonko Tsai, Deputy Representative of Japan-Taiwan Exchange Association Hattori Takashi, Director of Export Haruyuki Economic
Department of Japan-Taiwan Exchange Association, and President of Japan Taisei Plas Itabashi Masami. )

---